Cart (0 Items)
Your cart is currently empty.
View Products-
-
-
Monalizumab Biosimilar – Anti-KLRC1, NKG2A, CD159a, CD94 mAb – Research Grade
| Size | 100ug, 1MG |
|---|---|
| Isotype | IgG4, kappa |
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Clonality | Monoclonal Antibody |
| Expression system | Mammalian cells |
| Applications | Elisa, WB |
| Product name | Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade |
|---|---|
| Source | CAS 1228763-95-8 |
| Species | Humanized |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | Monalizumab,IPH-2201,NN-8765,NNC-0141-0000-0100,NNC-141-01000,anti-NKG2A,humZ270,KLRC1, NKG2A, CD159a, CD94,anti-KLRC1, NKG2A, CD159a, CD94 |
| Reference | PX-TA1392 |
| Note | For research use only. Not suitable for human use. |
| Isotype | IgG4-kappa |
| Clonality | Monoclonal Antibody |
Description of Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
General information on Anti-KLRC1/NKG2A/CD159a/CD94[Homo sapiens] (Monalizumab) Monoclonal Antibody
Monalizumab has been investigated for the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
Related products
Antigen
Human CD159a-KLRC1 recombinant protein
PX-P6098 500$
Isotype Control
Human IgG4 Isotype Control antibody
PTX17887 215$Contact us
Send us a message from the form below
Vele –
Great product!